Search Results - "Colussi, A.M."

PA.122 COMBINATION CHEMOTHERAPY (CT) WITH DOCETAXEL (D), OXALIPLATIN (O), CAPECITABINE (C) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (AGC): PRELIMINARY RESULTS ON TOXICITY OF A PILOT STUDY by Buonadonna, A, Cannizzaro, R, Colussi, A.M, Rosalen, S, Turchet, E, Tabaro, G, Frustaci, S

Get full text

The implications of GCP for the organisation of a Clinical Trial (CT) by Colussi, A.M.

Get full text

High dose chemotherapy (HDCT) and side effects by Colussi, A.M.

Get full text

Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer by Sorio, R., Robieux, I., Galligioni, E., Freschi, A., Colussi, A.M., Crivellari, D., Saracchini, S., Monfardini, S.

“…25 patients older than 65 years with metastatic breast cancer were treated with vinorelbine 30 mg/m 2 i.v. days 1 and 8 every 3 weeks; the pharmacokinetics…”
Get full text

Oral Etoposide in Elderly Patients with Advanced Non Small Cell Lung Cancer: A Clinical and Pharmacological Study by Sorio, R., Toffoli, G., Crivellari, D., Bearz, A., Corona, G., Colussi, A.M., Libra, M., Talamini, R., Veronesi, A.

“…Seventeen elderly patients with advanced progressive non small cell lung cancer (NSCLC) were treated with oral etoposide at the daily dose of 100 mg for 14…”
Get full text

The EORTC Clinical Research Coordinators Group by Fishwick, K, Berridge, J, Coffey, M, Colussi, A.M, Di Giulio, P, Marinus, A, Molin, C, Peters, M

“…The Clinical Research Coordinators Group (CRCG) is an umbrella organisation, compiled from four existing groups, namely the Oncology Nurses Group, the Data…”
Get full text

The elderly cancer patient: a nursing perspective by Colussi, A.M., Mazzer, L., Candotto, D., De Biasi, M., De Lorenzi, L., Pin, I., Pusiol, N., Romanin, C., Zamattio, V.

“…Since cancer incidence tends to increase with age, health professionals will encounter ever-greater numbers of older people with cancer. Elderly cancer…”
Get full text

505 Human carboxylesterase isoform 2 (hCE2) mRNA expression in peripheral blood lymphocytes as a predictive marker of irinotecan activation rate in vivo by Cecchin, E., Corona, G., Masier, S., Biason, P., Cattarossi, G., Frustaci, S., Buonadonna, A., Colussi, A.M., Boiocchi, M., Toffoli, G.

Get full text

1230 The clinical trial nurse in Italy: strategies for role preparation, implementation and evaluation by Bryce, J., Bell, C., Colussi, A.M., De Maio, G., Rossi, V.

Get full text

Pharmacology study of chronic oral idarubicin for breast cancer by Toffoli, G., Sorio, R., Aita, P., Crivellari, D., Corona, G., Bearz, A., Robieux, I., Colussi, A.M., Boiocchi, M., Veronesi, A.

Get full text

1430 Oral etoposide in the elderly with an associated pharmacokinetic (PK) study: The research nurse's contribution by Colussi, A.M., Ritossa, D., Morandin, A., Sorio, R.

“…For the elderly cancer patient (pt) standard intravenous chemotherapy (CT) treatments may cause many logistical problems as well as being costly in terms of…”
Get full text

Dose finding and pharmacokinetic (PK) study of daily oral Idarubicin (IDA) in metastatic breast cancer (MBC) by Sorio, R., Toffoll, G., Robieux, I., Rimondi, G., Aita, P., Corona, G., Crivellari, D., Colussi, A.M., Tumolo, S.

Get full text

853 Ifosfamide in continuous infusion: The pharmacokinetic profile in patients with soft tissue sarcomas by Comandone, A., Frustaci, S., Leone, L., Santoro, A., Oliva, C., Bretti, S., verusio, C., Colussi, A.M., Bumma, C.

“…Ifosfamide, an oxazophosphorin compound, active in mesenchimal tumours has recently been used at high doses (14–18 g/sqm) in order to increase the number of…”
Get full text

957 Bioavailability and pharmacokinetics of oral etoposide (VP16) in elderly patients by Robieux, I., Aita, P., Sorio, R., Lucenti, A., Freschi, A., Magri, D., Colussi, A.M., Vitali, V., Monfardini, S.

“…Chronic oral therapy with VP 16 in elderly patients (pts) is attractive for its efficacy in a variety of tumors, the ease of administration and good…”
Get full text

Pharmacokinetics of Ifosfamide Administered According to Three Different Schedules in Metastatic Soft Tissue and Bone Sarcomas by Comandone, A., Leone, L., Oliva, C., Frustaci, S., Monteleone, M., Colussi, A.M., Canton, O. Dal, Bergnolo, P., Boglione, A., Bumma, C.

“…Ifosfamide is a leading drug in soft tissue sarcoma therapy. Recently high dose therapy (>9 g/m 2 ) has been introduced in different schemes to obtain a higher…”
Get full text